NovoCure Limited (NVCR)
Largest Insider Buys in Sector
NVCR Stock Price History Chart
NVCR Stock Performance
About NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver …
Insider Activity of NovoCure Limited
Over the last 12 months, insiders at NovoCure Limited have bought $0 and sold $272,872 worth of NovoCure Limited stock.
On average, over the past 5 years, insiders at NovoCure Limited have bought $433,297 and sold $42.81M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,974 shares for transaction amount of $509,539 was made by Danziger Asaf (Chief Executive Officer) on 2021‑11‑26.
List of Insider Buy and Sell Transactions, NovoCure Limited
| 2024-11-02 | Sale | Chief Operating Officer | 44 <0.0001% | $16.69 | $734 | 0.00% | ||
| 2024-11-01 | Sale | EVP, Pres., Novocure Oncology | 598 0.0005% | $15.94 | $9,531 | +22.77% | ||
| 2024-11-01 | Sale | Chief Operating Officer | 160 0.0001% | $15.88 | $2,540 | +22.77% | ||
| 2024-10-31 | Sale | Chief Human Resources Officer | 810 0.0008% | $15.79 | $12,792 | +29.71% | ||
| 2024-08-02 | Sale | Chief Financial Officer | 688 0.0006% | $20.14 | $13,857 | -13.95% | ||
| 2024-06-04 | Sale | director | 964 0.0009% | $23.89 | $23,033 | -20.57% | ||
| 2024-06-04 | Sale | director | 964 0.0009% | $23.89 | $23,025 | -20.57% | ||
| 2024-06-04 | Sale | director | 964 0.0009% | $23.89 | $23,027 | -20.57% | ||
| 2024-03-04 | Sale | Chief Operating Officer | 1,217 0.0011% | $16.01 | $19,484 | +7.30% | ||
| 2024-03-04 | Sale | EVP, Pres., Novocure Oncology | 840 0.0008% | $16.01 | $13,448 | +7.30% | ||
| 2024-03-01 | Sale | Chief Operating Officer | 2,107 0.0019% | $16.03 | $33,769 | +8.37% | ||
| 2024-03-01 | Sale | EVP, Pres., Novocure Oncology | 1,679 0.0015% | $16.03 | $26,909 | +8.37% | ||
| 2024-02-28 | Sale | Chief Operating Officer | 2,303 0.0022% | $16.14 | $37,177 | +9.24% | ||
| 2024-02-28 | Sale | EVP, Pres., Novocure Oncology | 2,078 0.002% | $16.14 | $33,545 | +9.24% | ||
| 2023-11-07 | Sale | Chief Growth Officer | 382 0.0004% | $12.65 | $4,832 | +20.21% | ||
| 2023-09-01 | Sale | Chief Operating Officer | 294 0.0003% | $21.82 | $6,414 | -33.09% | ||
| 2023-09-01 | Sale | Chief Growth Officer | 273 0.0003% | $21.82 | $5,956 | -33.09% | ||
| 2023-09-01 | Sale | Chief Financial Officer | 883 0.0008% | $21.82 | $19,265 | -33.09% | ||
| 2023-08-02 | Sale | Chief Financial Officer | 1,144 0.0011% | $30.25 | $34,607 | -49.96% | ||
| 2023-03-07 | Sale | President, CNS Cancers US | 8,318 0.0079% | $75.16 | $625,205 | -73.25% |
Insider Historical Profitability
| Perlhagen Gert L. | director | 6125000 5.6608% | $30.83 | 1 | 1 | +171.79% |
| Shah Pritesh | Chief Growth Officer | 124511 0.1151% | $30.83 | 1 | 50 | +85.52% |
| MYLOD ROBERT J JR | director | 20000 0.0185% | $30.83 | 1 | 0 | <0.0001% |
| Danziger Asaf | Chief Executive Officer | 13583 0.0126% | $30.83 | 2 | 55 | <0.0001% |
Institutional Investor Ownership
| Fidelity Investments | $251.08M | 14.93 | 16.06M | +0.63% | +$1.58M | 0.02 | |
| The Vanguard Group | $156.67M | 9.32 | 10.02M | +2.71% | +$4.14M | <0.01 | |
| BlackRock | $141.99M | 8.44 | 9.08M | +3.33% | +$4.57M | <0.01 | |
| Capital International Investors | $138.55M | 8.24 | 8.86M | +0.03% | +$34,714.23 | 0.03 | |
| State Street | $52.56M | 3.13 | 3.36M | -12.96% | -$7.83M | <0.01 |